EndoDiagnosis & ENDOSURE Revolutionize Endometriosis Detection in Canada with 30-Minute Non-Invasive Test
In the past, diagnosing endometriosis required invasive laparoscopic surgery. This often meant that patients endured years of pain and a lower quality of life without a proper diagnosis. The ENDOSURE test offers a non-invasive option, boasting 99% accuracy in detecting all stages of the disease in less than an hour. This bypasses the need for surgical procedures. Learn more about EndoDiagnosis and what they offer by visiting their website.
This development is crucial for addressing a major gap in healthcare. Women suffering from endometriosis symptoms frequently face challenges in receiving the correct diagnosis and treatment. By providing a quick and effective diagnostic tool, ENDOSURE helps healthcare providers make faster, more informed decisions, improving care for those impacted by this chronic illness.
Maria Porcellato, CEO of EndoDiagnosis, stated, 'We have seen the desperation in patients, clients, and even our own daughters that comes with undiagnosed endometriosis. Our mission centers on empowering both patients and healthcare teams with the decision-support tools they need to make informed decisions about healthcare.'
The ENDOSURE Tier 1 test is designed for women of any age and provides results on the spot without the need for referrals or lab work. Its non-invasive nature not only spares patients from unnecessary surgical procedures but also enables healthcare professionals to concentrate on therapeutic strategies to manage the disease, preserving both quality of life and fertility.
EndoDiagnosis is not just distributing this advanced technology but is also dedicated to ensuring its successful use in clinics throughout Canada. The company offers training and certification for healthcare providers, professional medical education, and awareness programs, along with a provider directory to help patients find testing centers.
This initiative places Canada at the forefront of endometriosis care, allowing healthcare professionals to offer their patients both clarity and hope. Carolyn Plican, COO of EndoDiagnosis, stressed the importance of this development, commenting, 'This partnership represents more than a business agreement – it's about validating women's experiences and providing the answers they desperately need. When patients understand the root cause of their symptoms, it reduces stress, creates closure, and empowers them to move forward with effective treatment strategies.'
The ENDOSURE test is ready for immediate use by Canadian clinicians. Healthcare providers interested in adopting this test can contact EndoDiagnosis for details about installation, training, and certification opportunities. To further support education and awareness, EndoDiagnosis has launched the 'Endometriosis A to Z' podcast, which addresses all ages and stages of the disease, aiming to educate and empower its audience. Through this comprehensive resource, individuals can stay informed about endometriosis and its management.
EndoDiagnosis Inc. stands as the exclusive Canadian distributor of ENDOSURE, a non-invasive diagnostic test authorized by Health Canada that aids in the faster and more accurate diagnosis of endometriosis. Guided by a team of physicians and pharmacists, EndoDiagnosis is devoted to advancing women's health through innovative, science-based diagnostics and restorative reproductive care.
###
For more information about EndoDiagnosis Inc., contact the company here:
EndoDiagnosis Inc.Carolyn Plican1-833-439-3636
[email protected]
6903 142 Ave NW, Edmonton, AB T5C 2P1
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
an hour ago
- USA Today
Which states' air quality are most impacted by Canadian wildfires? See map.
As wildfires spread across Canada, air quality in the U.S. continues to be impacted, and people sensitive to air pollution could face "serious health effects," according to a government website that tracks air quality in the United States. There are 59 uncontrolled wildfires and 108 controlled wildfires across Canada as of Wednesday, July 30, the country's National Wildland Fire Situation Report said on its website. To date this year, there have been 3,582 fires. Fires have burned nearly 1.5 million acres since the start of 2025, according to the country's report. The smoke floating over the border shared between America and Canada is now impacting air quality in states as far south as Texas, AirNow's data shows. The EPA has declared the air quality in states near the Canadian border as "unhealthy or "unhealthy for sensitive groups." See maps and impacted states. See map of Canadian wildfires See map of US wildfires and smoke Which states are most affected by the Canadian fires? As of 9 a.m. ET on Tuesday, Aug. 5, areas in the following states are "Unhealthy for sensitive groups," according to AirNow: People with pre-existing medical conditions, like asthma, will be more sensitive to conditions that are deemed "Unhealthy for Sensitive Groups." "Members of sensitive groups may experience health effects," according to AirNow. 'Unhealthy' air quality States' air quality is measured by the EPA's U.S. Air Quality Index, according to AirNow's website. Values with an index of 151 to 200 are deemed unhealthy for all. As of 9 a.m. ET on Tuesday, Aug. 5, areas in the following states have been deemed unhealthy, according to AirNow's air quality map: "Some members of the general public may experience health effects," AirNow states on its website. However, "members of sensitive groups may experience more serious health effects." To learn if your area's air quality is affected by the wildfires, visit AirNow's interactive map. Side effects of inhaling wildfire smoke Wildfire smoke can irritate one's eyes, nose, and throat and cause the following symptoms: Particulate matter (PM) is one of the main components of wildfire smoke, comprised of small particles of solids or liquids suspended in the air, USA TODAY previously reported. According to Yale Medicine, the particles can be 10 micrometers, PM 10, or as small as 2.5 micrometers, PM 2.5, and the smaller one poses a lot of health risks. PM 2.5 is so tiny that it can easily pass people's usual defense mechanisms and go deep into their lungs. Not only can it damage lung function, but it can also pass into the bloodstream and travel to other organs. The following is linked to exposure to the PM 2.5: Julia is a trending reporter for USA TODAY. Connect with her on LinkedIn, X, Instagram, and TikTok: @juliamariegz, or email her at jgomez@
Yahoo
an hour ago
- Yahoo
Pharmacovigilance Automation Market Size, Key Players and Trends 2025
The pharmacovigilance automation market is gaining strong momentum worldwide, with projections indicating it will generate hundreds of millions in revenue between 2025 and 2034. Ottawa, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The pharmacovigilance automation market size growth is being driven by rising investments, ongoing innovation, and increasing demand across the healthcare and pharmaceutical sectors, a study published by Towards Healthcare a sister firm of Precedence Research. Get a free sample to explore key trends, market drivers, and growth insights: A key reason for this expansion is the tightening of global drug safety regulations and the need to better manage the growing number of adverse drug reactions. To meet these challenges, companies are turning to advanced technologies like artificial intelligence, natural language processing (NLP), and machine learning. These tools are helping automate tasks such as collecting, identifying, and analyzing adverse events making the process faster, more accurate, and cost-effective. Regionally, North America is leading the market thanks to heavy R&D spending by pharma companies and a strong digital healthcare infrastructure. Meanwhile, Asia Pacific is emerging as the fastest-growing region, driven by a high volume of clinical trials and a robust regulatory landscape. Key Takeaways North America is dominant in the pharmacovigilance automation market in 2024 with a 45% share. Asia Pacific is estimated to grow at the fastest CAGR from 2025 to 2035. By function, the case processing & reporting segment for the largest market revenue in 2024, with a 42% share. By function, the regulatory compliance automation segment is estimated to fastest-growing over the forecast period, 2025 to 2035. By technology, the robotic process automation (RPA) segment is dominant in the market in 2024 with a 36% share. By technology, the natural language processing (NLP) segment is expected to register the fastest growth over the forecast period, 2025 to 2035. By deployment mode, the cloud-based segment is dominant in the pharmacovigilance automation market in 2024, and it is expected to sustain the position during the forecast period with a 61% share. By end user, the pharmaceutical & biotechnology companies segment is dominant in the market in 2024 with a 48% share. By end user, the academic & research institutions segment is expected to register the fastest growth over the forecast period, 2025 to 2035. Market Overview & Potential What is the Growth Potential Responsible for the Growth of the Pharmacovigilance Automation Market? The growth of the market is driven by the growing demand and increasing drug development, fueled by the expanding pharmaceutical industry's demand for safety monitoring systems, which in turn fuels the growth of the market. The rising adverse drug reactions monitoring due to increasing chronic diseases demands effective pharmacovigilance practices. Other key growth drivers are the regulatory stringency, technological advancement to automate the task and improve the accuracy, and to streamline the assessment boosts the growth and expansion of the market. What are the Growing Trends Associated with the Pharmacovigilance Automation Market? AI and Machine Learning: AI and ML are increasingly utilized to automate various tasks such as identifying adverse events, extracting data from unstructured sources like social media, and monitoring literature. Automated Case Processing: Organizations are swiftly implementing automation for case handling, including intake, triage, and analysis, resulting in quicker reporting and greater efficiency. Big Data Analytics: Pharmacovigilance is employing big data analytics to detect patterns and correlations within large datasets, supporting signal detection and risk management. Real-World Evidence (RWE): The use of real-world data information collected outside clinical trials is on the rise, with automation playing a vital role in managing and analyzing this data effectively. Remote Work and Collaboration: The pandemic has sped up remote work adoption, and automation tools are facilitating improved collaboration and communication among pharmacovigilance teams. You can place an order or ask any questions, please feel free to contact us at sales@ What is the Growing Challenge in the Pharmacovigilance Automation Market? The key challenge that limits the growth of the Asia Pacific bioplastics market is the lack of sufficient funding for pharmacovigilance activities, resulting in limited implementation of advanced automation solutions, which limits the growth of the market. Other key challenge the is the shortage of skilled professionals who are experts in pharmacovigilance and automation technologies, which is a challenge and hinders the growth and expansion of the market. Regional Analysis How did North America Dominate the Pharmacovigilance Automation Market in 2024? North America dominated the pharmacovigilance automation market share by 45% in 2024, with a 45% share, driven by early adoption of automation in healthcare, including PV, which effectively manages inventory, orders, and tracking, ensuring proper medicine delivery and reducing errors. The FDA's Adverse Event Reporting System (FAERS) supports market growth by tracking adverse drug reactions and medication errors. Advanced technology infrastructure, stringent FDA regulations, and growing AI adoption promote pharmacovigilance automation. Emphasis on real-time data analytics, electronic health records integration, and robust drug safety frameworks drives automated adverse event reporting and signal detection to enhance patient safety and regulatory compliance. Canada's focus on digital health transformation, Health Canada's regulatory support, and investment in AI-powered pharmacovigilance tools promote automation. Collaboration among healthcare providers, researchers, and tech companies accelerates real-world data utilization, improving adverse event monitoring and drug safety through streamlined, automated reporting systems. What Made Asia Pacific Significantly Grow in the Pharmacovigilance Automation Market in 2024? The Asia Pacific region is projected to experience the fastest growth during the forecast period. Its rise is fueled by rapid product launches in healthcare, increasing consumer expectations, and the expanding use of digital health technology. Ongoing healthcare transformation, supported by policies, infrastructure development, and public-private partnerships, positions APAC to become a global leader in digital health, thus propelling market growth of market growth. China's expanding pharmaceutical industry, government initiatives for digital health, and adoption of big data and AI technologies drive pharmacovigilance automation. The National Medical Products Administration encourages automation to enhance drug safety surveillance, leveraging vast healthcare data to improve adverse event detection and regulatory oversight. India's growing pharmaceutical sector, government policies supporting digital health, and increased AI integration promote pharmacovigilance automation. The Central Drugs Standard Control Organization encourages automated adverse event reporting to enhance patient safety. Collaborative efforts between government, industry, and academia drive the adoption of technology for efficient drug safety monitoring. Get the latest insights on life science industry segmentation with our Annual Membership: Segmental Insights By function The case processing & reporting segment for the largest pharmacovigilance automation market revenue in 2024, with a 42% share. It provides data for investigating adverse effects, enabling the identification of new safety concerns and occasional assessment of the profit-to-challenge ratio for pharmaceutical use. It facilitates data exchange among stakeholders like patients, healthcare professionals, and authorities by sharing large volumes of safety information. Case reports play a key role in detecting new safety signals through the description of rare or delayed adverse effects that might not be observed in clinical trials. The regulatory compliance automation segment is estimated to fastest-growing over the forecast period, 2025 to 2035. Automation in regulatory compliance ensures that medications and healthcare devices meet strict standards of quality, safety, and efficacy before market release. Agencies such as the FDA, EMA, and WHO enforce guidelines like GMP, GCP, and GDP throughout all stages of development and distribution. Following these guidelines is crucial for maintaining public trust and ensuring success in the medical industry. By technology The robotic process automation (RPA) segment is dominant in the pharmacovigilance automation market in 2024 with a 36% share. Robotic process automation (RPA) enhances operational efficiency by streamlining workflows, reducing risks, and minimizing delays and rework, which lowers operational costs. RPA offers privacy and security benefits, helps pharmaceutical companies reduce human errors, and improves data accuracy to support better decision-making. In pharmacovigilance, RPA is especially valuable for faster adverse effect response times. The natural language processing (NLP) segment is expected to register the fastest growth over the forecast period, 2025 to 2035. NLP has become essential in pharmacovigilance, a field focused on monitoring and preventing drug-related adverse effects. It efficiently manages vast amounts of unstructured data such as patient records and social media posts, which provide real-world insights into drug effects. NLP aids in regulatory compliance and accelerates reporting to health authorities. By deployment mode The cloud-based segment is dominant in the pharmacovigilance automation market in 2024, and it is expected to sustain the position during the forecast period with a 61% share. Cloud solutions deliver robust security features like data encryption, secure access protocols, and regular backups. As an emerging tool, cloud-based systems in pharmacovigilance support seamless data integration by providing internet-based storage, computing services, analytics, and software, thus enhancing efficiency. By end user, The pharmaceutical & biotechnology companies segment is dominant in the pharmacovigilance automation market in 2024 with a 48% share. Pharmacovigilance companies share core goals with government agencies: protecting patients from harm by detecting hidden drug complexities early, identifying risk factors, debunking false safety signals, and addressing benefit challenges. PV raises awareness among healthcare professionals and patients regarding contraindications, indications, doses, administration routes, and adverse effects. The academic & research institutions segment is expected to register the fastest growth over the forecast period, 2025 to 2035. Pharmacovigilance also hosts leading research platforms that improve patient care through informed prescribing and ensure government compliance. These collaborations with top industry players further fuel market growth. Elevate your healthcare strategy with Towards Healthcare. Enhance efficiency and drive better outcomes schedule a call today: Recent Developments in the Pharmacovigilance Automation Market In July 2025, Tata Consultancy Services (TCS) was recognized as a Leader in Everest Group's PEAK Matrix for Pharmacovigilance (PV) Operations services. The report emphasizes TCS's extensive pharmacovigilance offerings, including device complaint management, medical device product quality issues, medical device reporting, and post-market surveillance as key strengths. TCS's flagship ADD safety platform is notably highlighted for its touchless processing of individual case safety reports (ICSRs), featuring integrated quality control, smart signal detection, literature surveillance, and safety report generation. In September 2024, Truliant Consulting releases a white paper titled AI and Automation in Pharmacovigilance: Transformative Trends and Future Outlook. This paper results from an open survey aimed at pharmaceutical companies to explore their adoption of artificial intelligence (AI) within their Pharmacovigilance (PV) frameworks. Top Companies and Their Contributions to the Market Company Contributions & Offerings Oracle Corporation Provides cloud-based safety and pharmacovigilance solutions, integrating AI for automated case processing and compliance management. Veeva Systems Inc. Offers cloud software tailored for life sciences, including pharmacovigilance modules that streamline safety data management and reporting. ArisGlobal Develops end-to-end drug safety and pharmacovigilance platforms with automation, AI, and regulatory compliance features. IQVIA Combines real-world data analytics with automation to enhance signal detection, adverse event reporting, and clinical safety workflows. Cognizant Technology Solutions Delivers IT and BPO services focusing on automated pharmacovigilance processes, leveraging AI and machine learning for data accuracy. Accenture Provides digital transformation and AI-driven pharmacovigilance automation services to optimize safety data workflows globally. Genpact Specializes in AI-powered pharmacovigilance automation, improving adverse event case processing and regulatory reporting efficiency. Tata Consultancy Services (TCS) Offers integrated technology solutions automating safety data capture, analysis, and regulatory submissions in pharmacovigilance. Parexel International Corporation Provides clinical research and safety automation services, enhancing pharmacovigilance with AI-enabled case management and reporting tools. ICON plc Focuses on clinical research and drug safety automation, utilizing advanced analytics and automated adverse event monitoring systems. Pharmacovigilance Automation Market Key Players List Oracle Corporation Veeva Systems Inc. ArisGlobal IQVIA Cognizant Technology Solutions Accenture Genpact Tata Consultancy Services (TCS) Parexel International Corporation ICON plc Capgemini SE PharmaLex GmbH Indegene Pvt Ltd BioClinica (part of ERT) Infosys Limited HCL Technologies Ennov Tech Mahindra Zifo RnD Solutions NNIT A/S Browse More Insights of Towards Healthcare: Global Pharmaceutical & Compounding Market Outlook (2024–2034) The pharmaceutical and healthcare packaging sectors are undergoing notable transformation, supported by rising demand for personalized treatments, automation, and regulatory compliance. Here's a breakdown of key market trajectories: GCC Compounding Pharmacy MarketThe GCC compounding pharmacy market is witnessing a strong upward trend. Valued at USD 16.39 million in 2024, it is expected to reach approximately USD 40.26 million by 2034, growing at a CAGR of 9.27%. This growth is driven by the increasing need for tailored medications across the Gulf region. Global Non-Sterile Compounding Pharmacy MarketThe non-sterile compounding pharmacy market was estimated at USD 5.97 billion in 2024 and is set to almost double by 2034, reaching around USD 12.11 billion. With a CAGR of 7.34%, the market reflects expanding demand for dosage flexibility and patient-specific drug formulations. Global Pharmacy Automation MarketThe pharmacy automation market is advancing rapidly as healthcare systems adopt technologies to streamline dispensing and improve safety. Starting at USD 6.35 billion in 2024, the market is projected to reach USD 16.65 billion by 2034, growing at a CAGR of 10.12%. Global Compounding Pharmacy MarketThe global compounding pharmacy market stood at USD 13.19 billion in 2023 and is projected to climb to USD 22.91 billion by 2034. This steady growth, at a CAGR of 5.15%, is propelled by rising chronic disease prevalence and the need for customized drug therapies. Global Vials Used in Compounding Pharmacy MarketThe vials used in compounding pharmacy market is set for strong revenue growth over the forecast period. The market is expanding in response to higher demand for safe and precise medication containers, especially in sterile compounding. Global Biotechnology & Pharmaceutical Services MarketThe biotechnology and pharmaceutical services market is projected to grow from USD 76.51 billion in 2024 to around USD 130.56 billion by 2034, at a CAGR of 5.48%. The market benefits from increased outsourcing, R&D intensity, and regulatory support. Global Biopharmaceuticals CRO MarketThe biopharmaceuticals CRO (Contract Research Organization) market is on a robust growth path. With rising R&D and a push for cost efficiency, the market is expected to generate significant revenue gains through 2034. Global Pharmaceutical Spray Drying MarketThe pharmaceutical spray drying market is valued at USD 2.37 billion in 2024 and forecast to nearly double, reaching USD 4.93 billion by 2034. A CAGR of 7.67% reflects the increased use of this technology for enhancing bioavailability in drug formulations. Global Ready-to-Use Pharmaceutical Packaging MarketThe ready-to-use pharmaceutical packaging market was valued at USD 10.4 billion in 2024 and is anticipated to reach USD 20.97 billion by 2034. Growing at a CAGR of 7.24%, this market is shaped by demand for efficiency, sterility, and compliance. Global Pharmaceutical Secondary Packaging MarketThe pharmaceutical secondary packaging market is estimated at USD 43.11 billion in 2024 and is expected to grow to USD 69.45 billion by 2034. With a CAGR of 4.94%, this segment is critical for safety labeling, tracking, and brand protection. Segments Covered in The Report By Function Case Processing & Reporting Case Intake Medical Review Data Entry & Coding Signal Detection & Management Literature Screening Regulatory Compliance Automation Risk Management & Benefit-Risk Evaluation Report Submission & Distribution Quality Control & Reconciliation By Technology Robotic Process Automation (RPA) Artificial Intelligence (AI) & Machine Learning Natural Language Processing (NLP) Cloud-Based PV Platforms Rules-Based Automation Tools Intelligent Automation By Deployment Mode On-Premises Cloud-Based By End User Pharmaceutical & Biotechnology Companies Contract Research Organizations (CROs) Pharmacovigilance Service Providers Regulatory Agencies Academic & Research Institutions By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait To invest in our premium strategic solution and customized market report options, click here: You can place an order or ask any questions, please feel free to contact us at sales@ Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire Find us on social platforms: LinkedIn | Twitter | InstagramError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Newsweek
2 hours ago
- Newsweek
Millions of Children Across 13 States Told To Limit Outdoor Activity
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Air quality alerts spanned at least 13 U.S. states on Tuesday, with sensitive groups urged to limit outdoor activity to avoid health risks. Why It Matters According to the Environmental Protection Agency, studies have linked particle pollution exposure to various health effects, including respiratory symptoms—such as coughing and wheezing, the development of asthma and increased susceptibility to respiratory infections. Authorities advise that during periods of poor air quality, sensitive groups—including children, older adults and those with certain preexisting conditions—should limit prolonged or heavy outdoor exertion. What To Know In collaboration with local agencies, the National Weather Service (NWS) published air quality alerts for the following states as of Tuesday morning: California Colorado Texas Minnesota Wisconsin Michigan Indiana Ohio Pennsylvania New York Connecticut Vermont New Hampshire Alerts spanned the entirety of Michigan and Wisconsin because of smoke from Canadian wildfires. "The main culprit remains Canadian wildfire smoke, originating from the Manitoba and Ontario Provinces. The second culprit is a stubborn high-pressure cell planted over the Midwest which is holding the smoke in place and compressing it close to the ground," said a notice from the Michigan Department of Environmental Quality, which the NWS published. "The weak clockwise winds will recirculate the worst of the smoke westward then northward, back into the western U.P., but the entire state will remain under hazy conditions during Tuesday," it continued. Northeast Minnesota and eastern Pennsylvania were also affected by wildfire smoke, according to alerts for the regions. Particle pollution—a product of wildfires—was also the cause of air quality alerts in Indiana, Vermont, New Hampshire and Colorado. Wildfire smoke from Canada will be on the increase over the next 24 hours. This is a model depiction of smoke in the atmosphere. Orange colors indicate thicker smoke, representing more hazy skies. #mewx #nhwx — NWS Gray (@NWSGray) August 2, 2025 In California, the South Coast Air Quality Management District issued a wildfire smoke advisory as multiple blazes burn in both central and Southern California. This included the 72,460-acre Gifford fire affecting parts of San Luis Obispo and Santa Barbara Counties, as well as the Rosa fire near the Santa Rosa Mountains and the Gold fire in the San Bernadino National Forest, north of Big Bear Lake. Here's a projection for the smoke from the #GiffordFire 🔥in San Luis Obispo/Santa Barbara Counties through tomorrow night. Smoke will generally move towards the south and east. — NWS Los Angeles (@NWSLosAngeles) August 4, 2025 Meanwhile, air quality alerts were in place in Texas and Ohio because of ozone pollution. In Ohio, this affected Ashtabula, Cuyahoga, Geauga, Lake, Lorain, Medina, Portage and Summit Counties. In Texas, alerts applied to both the Dallas-Fort Worth and Houston-Galveston areas. What People Are Saying AccuWeather meteorologist Dan Pydynowski told Newsweek on Friday: "Smoke and haze creating poor air quality at times will likely continue to be an issue in [the Great Lakes, Upper Midwest and central U.S.] through the weekend and into early next week. "The smoke/haze will gradually spread south and east later this weekend into early next week as well, perhaps getting into parts of the Northeast U.S. and the central-southern Plains too." The National Weather Service account for Burlington, Vermont, wrote on X on Thursday: "Air Quality Alerts continue for New York and Vermont. Some cleaner air is mixing in from the north compared to recent days, but some smoke will remain with higher concentrations expected in southern portions of the region." What Happens Next The NWS regularly issued forecast updates on its website.
